OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
104540$5050.0055

Corentec Co Ltd

Medical Equipment, Supplies & DistributionVerified

Corentec maintains a liquidity position with a current ratio of 1.61, indicating moderate short-term financial flexibility. The company's cash and equivalents amount to KRW 17,792,549,810, while its long-term debt stands at KRW 31,645,575,710, resulting in a net cash position that is negative after subtracting total debt. The price-to-book ratio of 0.82 suggests that the company's market value is below its book value, potentially indicating undervaluation or asset impairment concerns. Profitability metrics show a return on equity (ROE) of 7.99% and a return on assets (ROA) of 3.64%, both below the typical thresholds for high-performing firms in the healthcare equipment sector. The company's operating margin is 5.22% (calculated from operating income of KRW 5,247,421,210 on revenue of KRW 100,428,537,180), which is relatively modest compared to industry benchmarks. The company's revenue is concentrated in a single disclosed segment, with no geographic breakdown provided in the latest financials. This lack of diversification may expose Corentec to regional economic or regulatory risks, though the input data does not specify the geographic distribution of its revenue. Looking ahead, the company's revenue is projected to grow by a modest amount in the current fiscal year, with no significant acceleration expected in the next fiscal year. The capital expenditure of KRW -3,594,384,730 indicates a reduction in investment, which may signal a strategic shift or a focus on cost containment. The risk assessment highlights a medium liquidity risk, with the company's cash position not fully covering its long-term debt. The dilution risk is assessed as low, with no immediate pressure from share issuance or dilutive events. However, the negative net cash position suggests potential refinancing or liquidity management challenges in the near term. Recent filings and transcripts do not indicate any material events or strategic shifts in the company's operations. The absence of significant news may suggest a stable but unremarkable business environment for Corentec.

30-day price · 104540-690.00 (-12.5%)
Low$4720.00High$6100.00Close$4810.00As of22 May, 00:00 UTC
Profile
CompanyCorentec Co Ltd
Ticker104540.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Corentec Co Ltd operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to the market.

Classification. Corentec is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Corentec maintains a liquidity position with a current ratio of 1.61, indicating moderate short-term financial flexibility. The company's cash and equivalents amount to KRW 17,792,549,810, while its long-term debt stands at KRW 31,645,575,710, resulting in a net cash position that is negative after subtracting total debt. The price-to-book ratio of 0.82 suggests that the company's market value is below its book value, potentially indicating undervaluation or asset impairment concerns. Profitability metrics show a return on equity (ROE) of 7.99% and a return on assets (ROA) of 3.64%, both below the typical thresholds for high-performing firms in the healthcare equipment sector. The company's operating margin is 5.22% (calculated from operating income of KRW 5,247,421,210 on revenue of KRW 100,428,537,180), which is relatively modest compared to industry benchmarks. The company's revenue is concentrated in a single disclosed segment, with no geographic breakdown provided in the latest financials. This lack of diversification may expose Corentec to regional economic or regulatory risks, though the input data does not specify the geographic distribution of its revenue. Looking ahead, the company's revenue is projected to grow by a modest amount in the current fiscal year, with no significant acceleration expected in the next fiscal year. The capital expenditure of KRW -3,594,384,730 indicates a reduction in investment, which may signal a strategic shift or a focus on cost containment. The risk assessment highlights a medium liquidity risk, with the company's cash position not fully covering its long-term debt. The dilution risk is assessed as low, with no immediate pressure from share issuance or dilutive events. However, the negative net cash position suggests potential refinancing or liquidity management challenges in the near term. Recent filings and transcripts do not indicate any material events or strategic shifts in the company's operations. The absence of significant news may suggest a stable but unremarkable business environment for Corentec.
Key takeaways
  • Corentec's liquidity position is moderate, with a current ratio of 1.61 and a negative net cash position after subtracting long-term debt.
  • The company's ROE of 7.99% and ROA of 3.64% indicate below-average profitability for the healthcare equipment sector.
  • Revenue concentration in a single segment and lack of geographic diversification may increase exposure to regional risks.
  • The company is reducing capital expenditures, which may reflect a strategic shift or cost containment efforts.
  • Dilution risk is low, but liquidity risk remains a concern due to the negative net cash position.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$100.43B
Gross profit$52.09B
Operating income$5.25B
Net income$6.26B
R&D
SG&A
D&A
SBC
Operating cash flow$26.46B
CapEx-$3.59B
Free cash flow$6.46B
Total assets$171.93B
Total liabilities$93.58B
Total equity$78.35B
Cash & equivalents$17.79B
Long-term debt$31.65B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$100.43B$5.25B$6.26B$6.46B
FY-1$85.59B$2.26B-$2.58B-$2.86B
FY-2$92.05B$6.35B$4.06B-$1.71B
FY-3$63.91B$7.50B$1.78B-$195.1M
FY-4$44.63B$2.79B$763.9M-$4.49B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$171.93B$78.35B$17.79B
FY-1$186.27B$71.98B$17.14B
FY-2$187.13B$73.77B$17.05B
FY-3$171.82B$65.75B$15.71B
FY-4$118.90B$56.63B$13.56B
PeriodOCFCapExFCFSBC
FY0$26.46B-$3.59B$6.46B
FY-1-$6.61B-$6.13B-$2.86B
FY-2$2.63B-$11.83B-$1.71B
FY-3$10.60B-$6.70B-$195.1M
FY-4$4.08B-$8.56B-$4.49B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$28.61B$1.07B$3.21B$4.34B
FQ-1$25.77B$2.16B$1.14B$1.43B
FQ-2$23.42B$1.05B-$1.00B-$864.2M
FQ-3$22.63B$3.08B$2.91B$3.23B
FQ-4$26.24B$1.30B$37.1M$1.44B
FQ-5$19.80B$1.14B-$897.3M-$45.3M
FQ-6$20.51B-$206.0M-$1.81B-$1.86B
FQ-7$19.04B$22.5M-$304.1M-$2.74B
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$171.93B$78.35B$17.79B
FQ-1$175.16B$75.04B$26.34B
FQ-2$174.93B$73.77B$27.31B
FQ-3$173.36B$74.71B$21.95B
FQ-4$186.27B$71.98B$17.14B
FQ-5$173.59B$71.28B$11.13B
FQ-6$177.17B$72.23B$12.90B
FQ-7$174.44B$73.51B$8.22B
PeriodOCFCapExFCFSBC
FQ0$26.46B-$3.59B$4.34B
FQ-1$22.87B-$2.79B$1.43B
FQ-2$14.36B-$1.49B-$864.2M
FQ-3$3.26B-$779.6M$3.23B
FQ-4-$6.61B-$6.13B$1.44B
FQ-5-$11.66B-$5.27B-$45.3M
FQ-6-$10.86B-$4.58B-$1.86B
FQ-7-$9.54B-$2.98B-$2.74B
Valuation
Market price$5050.00
Market cap$64.57B
Enterprise value$78.42B
P/E10.3
Reported non-GAAP P/E
EV/Revenue0.8
EV/Op income14.9
EV/OCF3.0
P/B0.8
P/Tangible book0.8
Tangible book$78.35B
Net cash-$13.85B
Current ratio1.6
Debt/Equity0.4
ROA3.6%
ROE8.0%
Cash conversion4.2%
CapEx/Revenue-3.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric104540Activity
Op margin5.2%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin6.2%8.6% medp25 2.7% · p75 12.7%below median
Gross margin51.9%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-3.6%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity40.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-13 00:15 UTC#e482dc3a
Market quoteclose KRW 5050.00 · shares 0.01B diluted
no public URL
2026-05-13 00:15 UTC#423e232f
Source: analysis-pipeline (hybrid)Generated: 2026-05-13 00:18 UTCJob: 8fa75692